FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214374194> ?p ?o ?g. }

• W3214374194 abstract "Abstract Importance As SARS-CoV-2 pervades worldwide, considerable focus has been placed on the longer lasting health effects of the virus on the human host and on the anticipated healthcare needs. Objective The primary aim of this study is to examine the prevalence of post-acute sequelae of COVID-19 (PASC), commonly known as long COVID, across the world and to assess geographic heterogeneities through a systematic review and meta-analysis. A second aim is to provide prevalence estimates for individual symptoms that have been commonly reported as PASC, based on the existing literature. Data Sources PubMed, Embase, and iSearch for preprints from medRxiv, bioRxiv, SSRN, and others, were searched on July 5, 2021 with verification extending to August 12, 2021. Study Selection Studies written in English that consider PASC (indexed as ailments persisting at least 28 days after diagnosis or recovery for SARS-CoV-2 infection) and that examine corresponding prevalence, risk factors, duration, or associated symptoms were included. A total of 40 studies were included with 9 from North America, 1 from South America, 17 from Europe, 11 from Asia, and 2 from other regions. Data Extraction and Synthesis Data extraction was performed and separately cross-validated on the following data elements: title, journal, authors, date of publication, outcomes, and characteristics related to the study sample and study design. Using a random effects framework for meta-analysis with DerSimonian-Laird pooled inverse-variance weighted estimator, we provide an interval estimate of PASC prevalence, globally, and across regions. This meta-analysis considers variation in PASC prevalence by hospitalization status during the acute phase of infection, duration of symptoms, and specific symptom categories. Main Outcomes and Measures Prevalence of PASC worldwide and stratified by regions. Results Global estimated pooled PASC prevalence derived from the estimates presented in 29 studies was 0.43 (95% confidence interval [CI]: 0.35, 0.63), with a higher pooled PASC prevalence estimate of 0.57 (95% CI: 0.45, 0.68), among those hospitalized during the acute phase of infection. Females were estimated to have higher pooled PASC prevalence than males (0.49 [95% CI: 0.35, 0.63] versus 0.37 [95% CI: 0.24, 0.51], respectively). Regional pooled PASC prevalence estimates in descending order were 0.49 (95% CI: 0.21, 0.42) for Asia, 0.44 (95% CI: 0.30, 0.59) for Europe, and 0.30 (95% CI: 0.32, 0.66) for North America. Global pooled PASC prevalence for 30, 60, 90, and 120 days after index test positive date were estimated to be 0.36 (95% CI: 0.25, 0.48), 0.24 (95% CI: 0.13, 0.39), 0.29 (95% CI: 0.12, 0.57) and 0.51 (95% CI: 0.42, 0.59), respectively. Among commonly reported PASC symptoms, fatigue and dyspnea were reported most frequently, with a prevalence of 0.23 (95% CI: 0.13, 0.38) and 0.13 (95% CI: 0.09, 0.19), respectively. Conclusions and Relevance The findings of this meta-analysis suggest that, worldwide, PASC comprises a significant fraction (0.43 [95% CI: 0.35, 0.63]) of COVID-19 tested positive cases and more than half of hospitalized COVID-19 cases, based on available literature as of August 12, 2021. Geographic differences appear to exist, as lowest to highest PASC prevalence is observed for North America (0.30 [95% CI: 0.32, 0.66]) to Asia (0.49 [95% CI: 0.21, 0.42]). The case-mix across studies, in terms of COVID-19 severity during the acute phase of infection and variation in the clinical definition of PASC, may explain some of these differences. Nonetheless, the health effects of COVID-19 appear to be prolonged and can exert marked stress on the healthcare system, with 237M reported COVID-19 cases worldwide as of October 12, 2021. Key Points Question Among those infected with COVID-19, what is the global and regional prevalence of post-acute sequelae COVID-19 (PASC)? Findings Globally, the pooled PASC prevalence estimate was 0.43, whereas the pooled PASC prevalence estimate for patients who had to be hospitalized due to COVID-19 was 0.57. Regionally, estimated pooled PASC prevalence from largest to smallest effect size were 0.49 for Asia, 0.44 for Europe, and 0.30 for North America. Global pooled PASC prevalence for 30, 60, 90, and 120 days after index date were estimated to be 0.36, 0.24, 0.29, and 0.51, respectively. Among commonly reported PASC symptoms, fatigue and dyspnea were reported most frequently, with a prevalence of 0.23 and 0.13. Meaning In follow-up studies of patients with COVID-19 infections, PASC was common both globally and across geographic regions, with studies from Asia reporting the highest prevalence." @default.
• W3214374194 created "2021-11-22" @default.
• W3214374194 creator A5001290752 @default.
• W3214374194 creator A5006257131 @default.
• W3214374194 creator A5049804837 @default.
• W3214374194 creator A5063253432 @default.
• W3214374194 creator A5067833063 @default.
• W3214374194 creator A5082251592 @default.
• W3214374194 date "2021-11-16" @default.
• W3214374194 modified "2023-10-12" @default.
• W3214374194 title "Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review" @default.
• W3214374194 cites W2040745597 @default.
• W3214374194 cites W2090771116 @default.
• W3214374194 cites W2125435699 @default.
• W3214374194 cites W2560438049 @default.
• W3214374194 cites W2801697966 @default.
• W3214374194 cites W2889266241 @default.
• W3214374194 cites W3036527335 @default.
• W3214374194 cites W3037162821 @default.
• W3214374194 cites W3037259757 @default.
• W3214374194 cites W3041493976 @default.
• W3214374194 cites W3091990645 @default.
• W3214374194 cites W3097274327 @default.
• W3214374194 cites W3115058895 @default.
• W3214374194 cites W3118964757 @default.
• W3214374194 cites W3120213616 @default.
• W3214374194 cites W3120387768 @default.
• W3214374194 cites W3123665615 @default.
• W3214374194 cites W3131025738 @default.
• W3214374194 cites W3133321008 @default.
• W3214374194 cites W3133513065 @default.
• W3214374194 cites W3135021495 @default.
• W3214374194 cites W3135108774 @default.
• W3214374194 cites W3135566123 @default.
• W3214374194 cites W3135751767 @default.
• W3214374194 cites W3136114216 @default.
• W3214374194 cites W3136955306 @default.
• W3214374194 cites W3137954447 @default.
• W3214374194 cites W3138791341 @default.
• W3214374194 cites W3144543375 @default.
• W3214374194 cites W3148333766 @default.
• W3214374194 cites W3149633446 @default.
• W3214374194 cites W3149925030 @default.
• W3214374194 cites W3154047930 @default.
• W3214374194 cites W3154784838 @default.
• W3214374194 cites W3156925994 @default.
• W3214374194 cites W3157929118 @default.
• W3214374194 cites W3159095955 @default.
• W3214374194 cites W3159543693 @default.
• W3214374194 cites W3161777646 @default.
• W3214374194 cites W3162528078 @default.
• W3214374194 cites W3162967337 @default.
• W3214374194 cites W3163453245 @default.
• W3214374194 cites W3165456356 @default.
• W3214374194 cites W3165522334 @default.
• W3214374194 cites W3165862670 @default.
• W3214374194 cites W3166304141 @default.
• W3214374194 cites W3168298404 @default.
• W3214374194 cites W3169202226 @default.
• W3214374194 cites W3173883193 @default.
• W3214374194 cites W3175494759 @default.
• W3214374194 cites W3175779801 @default.
• W3214374194 cites W3176120582 @default.
• W3214374194 cites W3176995559 @default.
• W3214374194 cites W3191897276 @default.
• W3214374194 cites W3194737219 @default.
• W3214374194 cites W3202014360 @default.
• W3214374194 cites W3210555019 @default.
• W3214374194 cites W4205856400 @default.
• W3214374194 cites W4205916558 @default.
• W3214374194 cites W4226391429 @default.
• W3214374194 cites W4237506232 @default.
• W3214374194 doi "https://doi.org/10.1101/2021.11.15.21266377" @default.
• W3214374194 hasPublicationYear "2021" @default.
• W3214374194 type Work @default.
• W3214374194 sameAs 3214374194 @default.
• W3214374194 citedByCount "42" @default.
• W3214374194 countsByYear W32143741942021 @default.
• W3214374194 countsByYear W32143741942022 @default.
• W3214374194 countsByYear W32143741942023 @default.
• W3214374194 crossrefType "posted-content" @default.
• W3214374194 hasAuthorship W3214374194A5001290752 @default.
• W3214374194 hasAuthorship W3214374194A5006257131 @default.
• W3214374194 hasAuthorship W3214374194A5049804837 @default.
• W3214374194 hasAuthorship W3214374194A5063253432 @default.
• W3214374194 hasAuthorship W3214374194A5067833063 @default.
• W3214374194 hasAuthorship W3214374194A5082251592 @default.
• W3214374194 hasBestOaLocation W32143741941 @default.
• W3214374194 hasConcept C126322002 @default.
• W3214374194 hasConcept C144024400 @default.
• W3214374194 hasConcept C149923435 @default.
• W3214374194 hasConcept C2777466982 @default.
• W3214374194 hasConcept C2779134260 @default.
• W3214374194 hasConcept C2779473830 @default.
• W3214374194 hasConcept C3007834351 @default.
• W3214374194 hasConcept C3008058167 @default.
• W3214374194 hasConcept C44249647 @default.
• W3214374194 hasConcept C524204448 @default.
• W3214374194 hasConcept C55493867 @default.
• W3214374194 hasConcept C71924100 @default.

• next